{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:07:45Z","timestamp":1792886865263,"version":"4.5.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>It is unclear whether the effects of intensive vs standard blood pressure (BP) targets seen in clinical trials generalize to patients with chronic kidney disease (CKD) encountered in everyday practice due to differences in the distribution of cardiovascular risk factors and coexisting conditions.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate whether the beneficial and adverse effects of intensive vs standard BP control observed in the Systolic Blood Pressure Intervention Trial (SPRINT) are transportable to a target population of adults with CKD in clinical practice.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This comparative effectiveness study identified 2 populations with CKD who met the eligibility criteria for SPRINT between January 1 and December 31, 2019, in the Veterans Health Administration (VHA) and Kaiser Permanente of Southern California (KPSC). Baseline covariate, treatment, and outcome data from SPRINT were combined with covariate data from these populations to estimate the treatment effects in the target population, applying models that estimated outcomes using distributions in the trial. Analysis was performed between May 2023 and October 2024.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcomes were major cardiovascular events, all-cause death, cognitive impairment, CKD progression, and adverse events at 4 years.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 85\u202f938 patients (mean [SD] age, 75.7 [10.0] years; 81\u202f628 [95.0%] male) from the VHA and 13\u202f983 patients (mean [SD] age, 77.4 [9.6] years; 5371 [38.4%] male) from KPSC were included. Compared with 9361 SPRINT participants (mean [SD] age, 67.9 [9.4] years; 6029 [64.4%] male), these patients were older, had less prevalent cardiovascular disease, higher albuminuria, and used more statins. The associations of intensive vs standard BP control with major cardiovascular events, all-cause death, and adverse events were transportable from the trial to the VHA and KPSC populations; however, the trial\u2019s effects on cognitive and CKD outcomes were not transportable in 1 or both clinical populations. Intensive vs standard BP treatment was associated with lower absolute risks for major cardiovascular events at 4 years by 5.1% (95% CI, \u22129.8% to 3.2%) in the VHA population and 3.0% (95% CI, \u22126.3% to 0.3%) in the KPSC population and higher risks for adverse events by 1.3% (95% CI, \u22125.5% to 7.7%) in the VHA population and 3.1% (95% CI, \u22121.5% to 8.3%) in the KPSC population.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this comparative effectiveness study, the reduction in fatal and nonfatal cardiovascular end points and the increase in adverse events observed in SPRINT were largely transportable to trial-eligible CKD populations from clinical practice, suggesting benefits of implementing intensive BP targets.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.53458","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T16:01:56Z","timestamp":1736265716000},"page":"e2453458","source":"Crossref","is-referenced-by-count":8,"title":["SPRINT Treatment Among Adults With Chronic Kidney Disease From 2 Large Health Care Systems"],"prefix":"10.1001","volume":"8","author":[{"given":"Manjula","family":"Kurella Tamura","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California"},{"name":"Geriatric Research, Education and Clinical Center, VA Palo Alto, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Huang","sequence":"additional","affiliation":[{"name":"Geriatric Research, Education and Clinical Center, VA Palo Alto, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaejin","family":"An","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengnan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Sim","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas M.","family":"Pajewski","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Gaussoin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California"},{"name":"Department of Epidemiology and Population Health, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle C.","family":"Odden","sequence":"additional","affiliation":[{"name":"Geriatric Research, Education and Clinical Center, VA Palo Alto, Palo Alto, California"},{"name":"Department of Epidemiology and Population Health, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara I.","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Charu","sequence":"additional","affiliation":[{"name":"Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, California"},{"name":"Department of Pathology, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Montez-Rath","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"issue":"3","key":"zoi241495r1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","article-title":"Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease.","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"issue":"22","key":"zoi241495r2","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control.","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi241495r3","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD.","volume":"28","author":"Cheung","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"zoi241495r4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jama.2018.21442","article-title":"Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial.","volume":"321","author":"Williamson","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"zoi241495r5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/HYPERTENSIONAHA.121.18434","article-title":"Is the KDIGO systolic blood pressure target <120 mm Hg for chronic kidney disease appropriate in routine clinical practice?","volume":"79","author":"Dasgupta","year":"2022","journal-title":"Hypertension"},{"issue":"3","key":"zoi241495r6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1053\/j.ajkd.2021.09.013","article-title":"KDOQI US commentary on the 2021 KDIGO clinical practice guideline for the management of blood pressure in CKD.","volume":"79","author":"Drawz","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"17","key":"zoi241495r7","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1161\/CIRCULATIONAHA.116.025322","article-title":"Potential deaths averted and serious adverse events incurred from adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) intensive blood pressure regimen in the United States: projections from NHANES (National Health and Nutrition Examination Survey).","volume":"135","author":"Bress","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"zoi241495r8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1001\/jamainternmed.2020.0051","article-title":"Generalizability of clinical trials supporting the 2017 American College of Cardiology\/American Heart Association blood pressure guideline.","volume":"180","author":"Anderson","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"7","key":"zoi241495r9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019707","article-title":"Characteristics of populations excluded from clinical trials supporting intensive blood pressure control guidelines.","volume":"10","author":"Anderson","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"zoi241495r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0005","article-title":"Assessment of risk of harm associated with intensive blood pressure management among patients with hypertension who smoke: a secondary analysis of the Systolic Blood Pressure Intervention Trial.","volume":"2","author":"Scarpa","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi241495r11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/joim.12701","article-title":"Estimated glomerular filtration rate and the risk-benefit profile of intensive blood pressure control amongst nondiabetic patients: a post hoc analysis of a randomized clinical trial.","volume":"283","author":"Obi","year":"2018","journal-title":"J Intern Med"},{"issue":"10022","key":"zoi241495r12","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"zoi241495r13","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1001\/jamainternmed.2014.3279","article-title":"Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease.","volume":"174","author":"Kovesdy","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"2","key":"zoi241495r14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1161\/CIRCULATIONAHA.121.056878","article-title":"Estimation of DAPT study treatment effects in contemporary clinical practice: findings from the EXTEND-DAPT study.","volume":"145","author":"Butala","year":"2022","journal-title":"Circulation"},{"issue":"19","key":"zoi241495r15","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.jcin.2021.08.006","article-title":"Applicability of transcatheter aortic valve replacement trials to real-world clinical practice: findings from EXTEND-CoreValve.","volume":"14","author":"Butala","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"zoi241495r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.46295","article-title":"Comparing lung cancer screening strategies in a nationally representative US population using transportability methods for the National Lung Cancer Screening Trial.","volume":"7","author":"Robertson","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi241495r17","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/EDE.0000000000001633","article-title":"An overview of current methods for real-world applications to generalize or transport clinical trial findings to target populations of interest.","volume":"34","author":"Ling","year":"2023","journal-title":"Epidemiology"},{"issue":"20","key":"zoi241495r18","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","article-title":"Final report of a trial of intensive versus standard blood-pressure control.","volume":"384","author":"Lewis","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi241495r19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031742","article-title":"Representation of real-world adults with chronic kidney disease in clinical trials supporting blood pressure treatment targets.","volume":"13","author":"Li","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"zoi241495r20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002410","article-title":"Benefit and harm of intensive blood pressure treatment: derivation and validation of risk models using data from the SPRINT and ACCORD trials.","volume":"14","author":"Basu","year":"2017","journal-title":"PLoS Med"},{"issue":"25","key":"zoi241495r21","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"7","key":"zoi241495r22","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/jech.2004.029496","article-title":"Estimating causal effects from epidemiological data.","volume":"60","author":"Hern\u00e1n","year":"2006","journal-title":"J Epidemiol Community Health"},{"issue":"30","key":"zoi241495r23","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1002\/sim.3064","article-title":"Flexible parametric models for relative survival, with application in coronary heart disease.","volume":"26","author":"Nelson","year":"2007","journal-title":"Stat Med"},{"issue":"5","key":"zoi241495r24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/jamia\/ocy188","article-title":"An outcome model approach to transporting a randomized controlled trial results to a target population.","volume":"26","author":"Goldstein","year":"2019","journal-title":"J Am Med Inform Assoc"},{"key":"zoi241495r25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1146\/annurev-statistics-042522-103837","article-title":"A review of generalizability and transportability.","volume":"10","author":"Degtiar","year":"2023","journal-title":"Annu Rev Stat Appl"},{"issue":"3","key":"zoi241495r26","first-page":"1","article-title":"Multivariate imputation by chained equations in R.","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"issue":"1","key":"zoi241495r29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/10618600.2017.1356325","article-title":"Estimating individual treatment effect in observational data using random forest methods.","volume":"27","author":"Lu","year":"2018","journal-title":"J Comput Graph Stat"},{"issue":"10","key":"zoi241495r30","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/archinternmed.2011.32","article-title":"Effects of benefits and harms on older persons\u2019 willingness to take medication for primary cardiovascular prevention.","volume":"171","author":"Fried","year":"2011","journal-title":"Arch Intern Med"},{"issue":"10","key":"zoi241495r31","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1001\/jamainternmed.2017.4377","article-title":"Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis.","volume":"177","author":"Malhotra","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"16","key":"zoi241495r32","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.jacc.2021.02.058","article-title":"Patient selection for intensive blood pressure management based on benefit and adverse events.","volume":"77","author":"Bress","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"zoi241495r33","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/cpt.1633","article-title":"Nonrandomized real-world evidence to support regulatory decision making: process for a randomized trial replication project.","volume":"107","author":"Franklin","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"zoi241495r34","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M18-3668","article-title":"The Predictive Approaches to Treatment effect Heterogeneity (PATH) statement: explanation and elaboration.","volume":"172","author":"Kent","year":"2020","journal-title":"Ann Intern Med"},{"issue":"12","key":"zoi241495r35","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/jamainternmed.2020.5028","article-title":"Concordance between blood pressure in the systolic blood pressure intervention trial and in routine clinical practice.","volume":"180","author":"Drawz","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"4","key":"zoi241495r36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.122.009258","article-title":"Quantifying blood pressure visit-to-visit variability in the real-world setting: a retrospective cohort study.","volume":"16","author":"Lu","year":"2023","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"zoi241495r27","unstructured":"Ishwaran? H, Kogalur? UB. Fast united random forests for survival, regression, and classification. Accessed November 25, 2024. https:\/\/cran.r-project.org\/web\/packages\/randomForestSRC\/randomForestSRC.pdf"},{"key":"zoi241495r28","unstructured":"Ling? AY, Montez-Rath? ME, Kapphahn? K, Desai? M. Application of multiple imputation when using propensity score methods to generalize clinical trials to target populations of interest.? arXiv. Preprint posted online February 2, 2022. doi:10.48550\/arXiv.2202.00827"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2828755\/kurella_tamura_2025_oi_241495_1734984857.01331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T16:01:59Z","timestamp":1736265719000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2828755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.53458","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]}}}